Top

Published in:

01-01-2012 | Original Article

Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats

Authors: Motoya Chikakiyo, Mitsuo Shimada, Toshihiro Nakao, Jun Higashijima, Kozo Yoshikawa, Masanori Nishioka, Takashi Iwata, Nobuhiro Kurita

Published in: Surgery Today | Issue 1/2012

Abstract

Purpose

The key anticancer agent, CPT-11 (irinotecan hydrochloride), induces severe diarrhea clinically. We investigated the effect of a Kampo medicine, Dai-kenchu-to (DKT), on CPT-11-induced intestinal injuries in rats.

Methods

Twenty-four male Wistar rats were divided into three groups: a control group; a CPT-11 group, given CPT-11 150 mg/kg intraperitoneally for 2 days; and a DKT group, given DKT 300 mg/kg orally for 5 days with CPT-11 150 mg/kg intraperitoneally on days 4 and 5. The rats were killed on day 6.

Results

Interleukin (IL)-1β, IL-12, interferon (IFN)-γ, and tumor necrosis factor-α expression in the small intestine of the CPT-11 group was significantly higher than that of the control group. Interleukin-1β and IFN-γ expression was improved significantly by DKT (P < 0.05). The number and height of jejuna villi, injury score, and apoptosis index in the CPT-11 group were improved significantly by DKT (P < 0.05).

Conclusions

DKT suppressed CPT-11 induced inflammatory cytokines and apoptosis in the intestinal mucosa and maintained the mucosal integrity.

Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993;11:909–13.PubMed

Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22:2849–55.PubMedCrossRef

Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990;8:1907–12.PubMed

Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.PubMedCrossRef

Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56:3752–7.PubMed

Tallman MN, Miles KK, Kessler FK, Nielsen JN, Tian X, Ritter JK, et al. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther. 2007;320:29–37.PubMedCrossRef

Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, et al. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats. Cancer Chemother Pharmacol. 2008;61:595–605.PubMedCrossRef

Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev. 2004;30:555–62.PubMedCrossRef

Itoh T, Yamakawa J, Mai M, Yamaguchi N, Kanda T. The effect of the herbal medicine Dai-kenchu-to on post-operative ileus. J Int Med Res. 2002;30:428–32.PubMed

10.

Satoh K, Kase Y, Hayakawa T, Murata P, Ishige A, Sasaki H. Dai-kenchu-to enhances accelerated small intestinal movement. Biol Pharm Bull. 2001;24:1122–6.PubMedCrossRef

11.

Yoshikawa K, Kurita N, Higashijima J, Miyatani T, Miyamoto H, Nishioka M, et al. Kampo medicine “Dai-kenchu-to” prevents bacterial translocation in rats. Dig Dis Sci. 2008;53:1824–31.PubMedCrossRef

12.

Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol. 2003;18:1095–100.PubMedCrossRef

13.

Fukuda H, Chen C, Mantyh C, Ludwig K, Pappas TN, Takahashi T. The herbal medicine, Dai-kenchu-to, accelerates delayed gastrointestinal transit after the operation in rats. J Surg Res. 2006;131:290–5.PubMedCrossRef

14.

Gurbuz AT, Kunzelman J, Ratzer EE. Supplemental dietary arginine accelerates intestinal mucosal regeneration and enhances bacterial clearance following radiation enteritis in rats. J Surg Res. 1998;74:149–54.PubMedCrossRef

15.

Demirer S, Aydintug S, Aslim B, Kepenekci I, Sengül N, Evirgen O, et al. Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition. 2006;22:179–86.PubMedCrossRef

16.

Iskit SH, Tugtepe H, Ayyildiz SH, Kotiloglu E, Dagli TE, Yeğen BC. Epidermal growth factor and bombesin act synergistically to support intestinal adaptation in rats with massive small bowel resection. Pediatr Surg Int. 2005;21:436–40.PubMedCrossRef

17.

Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg. 1970;101:478–83.PubMedCrossRef

18.

Hang CH, Shi JX, Sun BW, Li JS. Apoptosis and functional changes of dipeptide transporter in the rat small intestine after traumatic brain injury. J Surg Res. 2006;137:53–60.PubMedCrossRef

19.

Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst. 1995;87:1876–83.PubMedCrossRef

20.

Kase Y, Hayakawa T, Aburada M, Komatsu Y, Kamataki T. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol. 1997;75:407–13.PubMedCrossRef

21.

Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther. 2007;6:1449–54.PubMedCrossRef

22.

Melo ML, Brito GA, Soares RC, Carvalho SB, Silva JV, Soares PM, et al. Role of cytokines (TNFα, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol. 2008;61:775–84.PubMedCrossRef

23.

Torisu M, Murakami H, Akbar F, Matsui H, Hiasa Y, Matsuura B, et al. Protective role of interleukin-10-producing regulatory dendritic cells against murine autoimmune gastritis. J Gastroenterol. 2008;43:100–7.PubMedCrossRef

24.

Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol. 2009;44:26–46.PubMedCrossRef

25.

Tagawa M. Cytokine therapy for cancer. Curr Pharm Des. 2006;6:681–99.CrossRef

26.

Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.PubMed

27.

Xing Z, Wang J. Consideration of cytokines as therapeutics agents or targets. Curr Pharm Des. 2000;6:599–611.PubMedCrossRef

28.

Hu ZP, Yang XX, Chan SY, Xu AL, Duan W, Zhu YZ, et al. St. John’s wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol. 2006;216:225–37.PubMedCrossRef

29.

Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007;33:448–60.PubMedCrossRef

30.

Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer. 2005;116:464–70.PubMedCrossRef

31.

Xue H, Sawyer MB, Field CJ, Dieleman LA, Murray D, Baracos VE. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr. 2008;138:740–6.PubMed

32.

Endo S, Nishida T, Nishikawa K, Nakajima K, Hasegawa J, Kitagawa T, et al. Dai-kenchu-to, a Chinese herbal medicine, improves stasis of patients with total gastrectomy and jejunal pouch interposition. Am J Surg. 2006;192:9–13.PubMedCrossRef

33.

Sato Y, Inoue S, Katagiri F, Itoh H, Takeyama M. Effects of pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans. Biol Pharm Bull. 2006;29:166–71.PubMedCrossRef

34.

Murata P, Kase Y, Ishige A, Sasaki H, Kurosawa S, Nakamura T. The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats. Life Sci. 2002;70:2061–70.PubMedCrossRef

35.

Kono T, Koseki T, Chiba S, Ebisawa Y, Chisato N, Iwamoto J. Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1. J Surg Res. 2008;150:78–84.PubMedCrossRef

Title: Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats
Authors: Motoya Chikakiyo
Mitsuo Shimada
Toshihiro Nakao
Jun Higashijima
Kozo Yoshikawa
Masanori Nishioka
Takashi Iwata
Nobuhiro Kurita
Publication date: 01-01-2012
Publisher: Springer Japan
Published in: Surgery Today / Issue 1/2012
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-011-0014-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Kampo medicine “Dai-kenchu-to” prevents CPT-11-induced small-intestinal injury in rats

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Acknowledgment to reviewers

Successful resection of a massive mediastinal liposarcoma that rapidly extended into the entire left thoracic cavity: report of a case

Totally laparoscopic colectomy with intracorporeal anastomosis achieved using a laparoscopic linear stapler: experience of a single institute

Side-to-side isoperistaltic strictureplasty for chronic ischemic enteritis: report of a case

Chylothorax after neck dissection for thyroid carcinomas: report of three cases

Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives